Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | RAD52 | P43351 | 1/20 | 0.32 |
| ▸ | GFER | P55789 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19230301 | 0.85 | HTT (0.39) | ALDH1A1KDM4EMAPT | |
| SCHEMBL18823850 | 0.81 | — | — | |
| SCHEMBL20227878 | 0.80 | ALDH1A1 (0.35) | POLBALDH1A1KDM4EMAPTKMT2A | |
| SCHEMBL19506632 | 0.80 | HRH3 (0.35) | ALDH1A1HRH3TSHR | |
| SCHEMBL12092210 | 0.79 | ALDH1A1 (0.37) | POLBALDH1A1KDM4EMAPTKMT2A | |
| SCHEMBL19606711 | 0.76 | ALDH1A1 (0.38) | ALDH1A1KDM4EKMT2ASMN1; SMN2GAA | |
| SCHEMBL20076357 | 0.76 | PKM (0.34) | POLBALDH1A1KDM4EMAPTKMT2A | |
| SCHEMBL15387288 | 0.75 | ALDH1A1 (0.35) | POLBALDH1A1KDM4EMAPTKMT2A | |
| SCHEMBL7907038 | 0.75 | ALDH1A1 (0.39) | POLBALDH1A1KDM4EMAPTKMT2A | |
| SCHEMBL16330538 | 0.75 | POLB (0.37) | POLBALDH1A1KDM4EMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10507209-B2 | Quinazoline derivatives substituted by aniline, preparation method and use thereof | XUANZHU PHARMA CO, LTD. (CN) | 2019-12-17 | — | — | US | disclosed |
| US-20170333433-A1 | QUINAZOLINE DERIVATIVES SUBSTITUTED BY ANILINE, PREPARATION METHOD AND USE THEREOF | XUANZHU PHARMA CO, LTD. (CN) | 2017-11-23 | — | — | US | disclosed |
| US-9730934-B2 | Quinazoline derivatives substituted by aniline, preparation method and use thereof | Xuanzhu Pharma Co., Ltd. (CN) | 2017-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170333433-A1 | QUINAZOLINE DERIVATIVES SUBSTITUTED BY ANILINE, PREPARATION METHOD AND USE THEREOF | NQO2, CHRM1, CHRM2 | POLB 1525/4885ALDH1A1 691/4885KDM4E 1939/4885 |
| US-10507209-B2 | Quinazoline derivatives substituted by aniline, preparation method and use thereof | NQO2, CHRM1, CHRM2 | POLB 1525/4885ALDH1A1 691/4885KDM4E 1939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.